Michel Orsinger, CEO of Synthes, will receive a $51.9 million payout as part of a $21.3 billion acquisition by Johnson & Johnson. The buyout, which is expected to be completed early next year, will allow Johnson & Johnson to add Synthes to its DePuy unit, with Orsinger taking over as head of the company's new global orthopedics team.

Related Summaries